The Ellie MD lawsuit landscape has two separate tracks: a consumer class action accusing the company of false advertising on its skincare and sunscreen products, and a federal court fight between founder Hanieh Sigari and her estranged husband Dariusz Banasik over Qyral, the company she left before starting Ellie MD. The two cases involve different parties, different claims, and different courts, and a customer or brand partner researching the company usually wants to know about the first while the second explains how Ellie MD came to exist.
The Consumer Class Action Over Skincare and Sunscreen
Consumers have sued Ellie MD alleging that its sunscreen and skincare line was falsely advertised. The plaintiffs claim SPF protection on products labeled SPF 30 and SPF 50 was overstated and never verified by independent accredited labs, that ingredient disclosures were incomplete or inaccurate, and that marketing phrases including “clinically tested,” “dermatologist approved,” “safe for sensitive skin,” and “non-toxic” were used without adequate scientific backing.1Lawfold. Ellie MD Lawsuit
The complaint invokes Section 5 of the Federal Trade Commission Act, state unfair and deceptive trade practices statutes, the California Consumer Legal Remedies Act, and New York General Business Law Sections 349 and 350. The alleged injury is economic: buyers say they paid premium prices for products that did not deliver the advertised efficacy or safety.1Lawfold. Ellie MD Lawsuit
As of mid-2026, the case is at the class certification stage, with the court deciding whether to let it proceed on behalf of a unified group of U.S. consumers who bought the products during a defined period. Settlement talks are reportedly active, and a resolution is expected later in 2026.1Lawfold. Ellie MD Lawsuit No settlement fund or claim process has been announced.
The Qyral Dispute Between the Founders
The corporate case that shaped Ellie MD’s origin is Sigari v. Banasik, filed in March 2024 in the Northern District of California. Sigari alleged that her co-founder and estranged husband locked her out of Qyral’s digital systems, cut off her phone and two-factor authentication, told employees she had been fired, and moved at least $150,000 out of a $240,000 operating account. She brought claims under the Computer Fraud and Abuse Act, civil RICO, and California statutes, and sought at least $10 million in damages plus a declaration that she remained Qyral’s CEO.2Andrew Watters Law. Sigari v. Banasik Complaint
Sigari then left Qyral and launched Ellie MD, mirroring Qyral’s product line and onboarding former Qyral distributors for as little as $1.3BehindMLM. Hanieh Sigari Abandons Qyral to Launch Ellie MD On June 7, 2024, Banasik obtained a temporary restraining order that halted Ellie MD’s operations the same day. The TRO blocked Ellie MD from selling the same compounded semaglutide and tirzepatide treatments Qyral offered and from soliciting Qyral’s consultants and vendors. Sigari was also ordered to account for funds transferred from Qyral after a court-appointed receiver took over.4BehindMLM. Ellie MD Business Operations Halted by Qyral TRO
The shutdown was brief. By June 13, 2024, the parties agreed to a modified TRO letting Ellie MD reopen and compete, on terms: consultants could choose either company, neither side could specifically solicit the other’s consultants, and neither could sell pharmaceutical products manufactured by the same pharmacy.5BehindMLM. Qyral TRO Modified to Allow Ellie MD to Operate
Qyral’s Dissolution and the FancyMeds Order
After a November 2024 status conference, the court ordered Qyral dissolved, with proof of dissolution of the California LLC due by January 31, 2025. A January 7, 2025 order dissolved all previous TROs and preliminary injunctions, and the receivership was terminated on March 25, 2025.6BehindMLM. Qyral to Be Dissolved, Receivership Terminated
A new flare-up followed almost immediately. On March 19, 2025, Sigari sought a fresh TRO, alleging Banasik had sent thousands of emails to former Qyral customers and promoters, using her name, to promote his new venture “FancyMeds.” The court granted the order on March 21, 2025, directing Banasik to stop sending communications from any Qyral entity accounts. Existing contempt proceedings against Banasik were terminated on March 27, and a scheduled September trial was vacated, though Sigari kept the right to file new contempt motions. As of a July 2025 status conference none had been filed, and the next hearing was set for August 28, 2025.6BehindMLM. Qyral to Be Dissolved, Receivership Terminated
Consumer Complaints Outside Court
Ellie MD is not accredited by the Better Business Bureau. Its BBB profile shows 17 consumer complaints filed over the past three years, 16 of them closed in the most recent 12 months. Product issues make up nine, service four, and sales and advertising practices two.7BBB. EllieMD LLC Complaints
Recurring themes are worth knowing if you buy from the company. Customers describe automatic subscription renewals they say were not clearly disclosed at checkout, difficulty removing stored payment information from the website, and a refund policy that bars returns of any compounded medication once dispensed, which the company attributes to safety and regulatory requirements. Some buyers have reported adverse reactions including fatigue, nausea, and injection-site pain, along with slow responses from the medical team on the portal. Others have challenged the company’s refusal to provide letters of medical necessity for FSA or HSA reimbursement despite marketing language suggesting the treatments could qualify.7BBB. EllieMD LLC Complaints
What Ellie MD Is Not Being Sued For
Two large enforcement stories in the compounded GLP-1 space do not involve Ellie MD. In March 2026 the FDA issued warning letters to 30 telehealth firms over false or misleading claims about compounded GLP-1s, including claims implying equivalence with FDA-approved drugs; the publicly available list of recipients does not name Ellie MD.8FDA. FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s Eli Lilly, maker of Mounjaro, sued several telehealth competitors selling compounded versions in April 2025, but those suits targeted Mochi Health, Willow Health, Fella Health, and Henry Meds, not Ellie MD.9NPR. Eli Lilly Sues Companies Selling Alternative Versions of Its Weight Loss Drug
One more clarification for anyone searching: Ellie MD (EllieMD LLC) is not the same company as Ellie Mental Health, a separate franchise business with its own unrelated litigation.